Pharmanest meets all efficacy and safety end points in Phase II study of SHACT

Home › Pharmanest meets all efficacy and safety end points in Phase II study of SHACT

August 1, 2013. Pharmanest AB announced today positive results from a Phase II-study investigating the efficacy and tolerability of SHACT.

24.11	Young people who refuse to work to lose benefits - minister
24.11	'I was scammed out of 75k by Martin Lewis deepfake advert'
23.11	'Trust and reserve judgement' on rebrand, says Jaguar
23.11	UK wants to hire EU negotiator to 'reset' relations
23.11	Sisters build global beauty brand from a garage
23.11	Versace bag for 15: Why Christmas shoppers are choosing charity shops
23.11	'We are being robbed': Homeowners feel trapped by rising fees
23.11	'We are being robbed': Homeowners feel trapped by rising fees
Consumer Goods and Services »

je.st